Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection.

Winer BY, Shirvani-Dastgerdi E, Bram Y, Sellau J, Low BE, Johnson H, Huang T, Hrebikova G, Heller B, Sharon Y, Giersch K, Gerges S, Seneca K, Pais MA, Frankel AS, Chiriboga L, Cullen J, Nahass RG, Lutgehetmann M, Toettcher JE, Wiles MV, Schwartz RE, Ploss A.

Sci Transl Med. 2018 Jun 27;10(447). pii: eaap9328. doi: 10.1126/scitranslmed.aap9328.

PMID:
29950446
2.

Hepatitis D Virus Infection of Mice Expressing Human Sodium Taurocholate Co-transporting Polypeptide.

He W, Ren B, Mao F, Jing Z, Li Y, Liu Y, Peng B, Yan H, Qi Y, Sun Y, Guo JT, Sui J, Wang F, Li W.

PLoS Pathog. 2015 Apr 22;11(4):e1004840. doi: 10.1371/journal.ppat.1004840. eCollection 2015 Apr.

3.

Sodium taurocholate cotransporting polypeptide is the limiting host factor of hepatitis B virus infection in macaque and pig hepatocytes.

Lempp FA, Wiedtke E, Qu B, Roques P, Chemin I, Vondran FWR, Le Grand R, Grimm D, Urban S.

Hepatology. 2017 Sep;66(3):703-716. doi: 10.1002/hep.29112. Epub 2017 Jul 18.

PMID:
28195359
4.

Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation.

Lütgehetmann M, Mancke LV, Volz T, Helbig M, Allweiss L, Bornscheuer T, Pollok JM, Lohse AW, Petersen J, Urban S, Dandri M.

Hepatology. 2012 Mar;55(3):685-94. doi: 10.1002/hep.24758. Epub 2012 Jan 30.

PMID:
22031488
5.

Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide.

Yan H, Peng B, Liu Y, Xu G, He W, Ren B, Jing Z, Sui J, Li W.

J Virol. 2014 Mar;88(6):3273-84. doi: 10.1128/JVI.03478-13. Epub 2014 Jan 3.

6.

Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes.

Ni Y, Lempp FA, Mehrle S, Nkongolo S, Kaufman C, Fälth M, Stindt J, Königer C, Nassal M, Kubitz R, Sültmann H, Urban S.

Gastroenterology. 2014 Apr;146(4):1070-83. doi: 10.1053/j.gastro.2013.12.024. Epub 2013 Dec 19.

PMID:
24361467
7.

A new HDV mouse model identifies mitochondrial antiviral signaling protein (MAVS) as a key player in IFN-β induction.

Suárez-Amarán L, Usai C, Di Scala M, Godoy C, Ni Y, Hommel M, Palomo L, Segura V, Olagüe C, Vales A, Ruiz-Ripa A, Buti M, Salido E, Prieto J, Urban S, Rodríguez-Frias F, Aldabe R, González-Aseguinolaza G.

J Hepatol. 2017 Oct;67(4):669-679. doi: 10.1016/j.jhep.2017.05.010. Epub 2017 May 18. Erratum in: J Hepatol. 2018 May 15;:.

PMID:
28527664
8.

Modification of Three Amino Acids in Sodium Taurocholate Cotransporting Polypeptide Renders Mice Susceptible to Infection with Hepatitis D Virus In Vivo.

He W, Cao Z, Mao F, Ren B, Li Y, Li D, Li H, Peng B, Yan H, Qi Y, Sun Y, Wang F, Sui J, Li W.

J Virol. 2016 Sep 12;90(19):8866-74. doi: 10.1128/JVI.00901-16. Print 2016 Oct 1.

9.

Hepatitis Delta co-infection in humanized mice leads to pronounced induction of innate immune responses in comparison to HBV mono-infection.

Giersch K, Allweiss L, Volz T, Helbig M, Bierwolf J, Lohse AW, Pollok JM, Petersen J, Dandri M, Lütgehetmann M.

J Hepatol. 2015 Aug;63(2):346-53. doi: 10.1016/j.jhep.2015.03.011. Epub 2015 Mar 17.

PMID:
25795587
10.

Evidence that hepatitis B virus replication in mouse cells is limited by the lack of a host cell dependency factor.

Lempp FA, Mutz P, Lipps C, Wirth D, Bartenschlager R, Urban S.

J Hepatol. 2016 Mar;64(3):556-64. doi: 10.1016/j.jhep.2015.10.030. Epub 2015 Nov 11.

PMID:
26576481
11.

Persistent hepatitis D virus mono-infection in humanized mice is efficiently converted by hepatitis B virus to a productive co-infection.

Giersch K, Helbig M, Volz T, Allweiss L, Mancke LV, Lohse AW, Polywka S, Pollok JM, Petersen J, Taylor J, Dandri M, Lütgehetmann M.

J Hepatol. 2014 Mar;60(3):538-44. doi: 10.1016/j.jhep.2013.11.010. Epub 2013 Nov 23.

PMID:
24280293
12.

Mouse models of hepatitis B and delta virus infection.

Dandri M, Lütgehetmann M.

J Immunol Methods. 2014 Aug;410:39-49. doi: 10.1016/j.jim.2014.03.002. Epub 2014 Mar 12.

PMID:
24631647
13.

Hepatitis delta virus persists during liver regeneration and is amplified through cell division both in vitro and in vivo.

Giersch K, Bhadra OD, Volz T, Allweiss L, Riecken K, Fehse B, Lohse AW, Petersen J, Sureau C, Urban S, Dandri M, Lütgehetmann M.

Gut. 2019 Jan;68(1):150-157. doi: 10.1136/gutjnl-2017-314713. Epub 2017 Dec 7.

PMID:
29217749
14.

Nucleic Acid Polymers Are Active against Hepatitis Delta Virus Infection In Vitro.

Beilstein F, Blanchet M, Vaillant A, Sureau C.

J Virol. 2018 Jan 30;92(4). pii: e01416-17. doi: 10.1128/JVI.01416-17. Print 2018 Feb 15.

15.

Molecular determinants of hepatitis B and D virus entry restriction in mouse sodium taurocholate cotransporting polypeptide.

Yan H, Peng B, He W, Zhong G, Qi Y, Ren B, Gao Z, Jing Z, Song M, Xu G, Sui J, Li W.

J Virol. 2013 Jul;87(14):7977-91. doi: 10.1128/JVI.03540-12. Epub 2013 May 15.

16.

Strategies to inhibit entry of HBV and HDV into hepatocytes.

Urban S, Bartenschlager R, Kubitz R, Zoulim F.

Gastroenterology. 2014 Jul;147(1):48-64. doi: 10.1053/j.gastro.2014.04.030. Epub 2014 Apr 25. Review.

PMID:
24768844
17.

Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options.

Lempp FA, Ni Y, Urban S.

Nat Rev Gastroenterol Hepatol. 2016 Oct;13(10):580-9. doi: 10.1038/nrgastro.2016.126. Epub 2016 Aug 18. Review.

PMID:
27534692
18.

Use of FDA approved therapeutics with hNTCP metabolic inhibitory properties to impair the HDV lifecycle.

Blanchet M, Sureau C, Labonté P.

Antiviral Res. 2014 Jun;106:111-5. doi: 10.1016/j.antiviral.2014.03.017. Epub 2014 Apr 6.

PMID:
24717262
19.

Hepatitis Delta Virus: Replication Strategy and Upcoming Therapeutic Options for a Neglected Human Pathogen.

Lempp FA, Urban S.

Viruses. 2017 Jul 4;9(7). pii: E172. doi: 10.3390/v9070172. Review.

20.

Hepatitis B Virus Therapeutic Agent ARB-1740 Has Inhibitory Effect on Hepatitis Delta Virus in a New Dually-Infected Humanized Mouse Model.

Ye X, Tateno C, Thi EP, Kakuni M, Snead NM, Ishida Y, Barnard TR, Sofia MJ, Shimada T, Lee ACH.

ACS Infect Dis. 2019 May 10;5(5):738-749. doi: 10.1021/acsinfecdis.8b00192. Epub 2018 Nov 20.

PMID:
30408957

Supplemental Content

Support Center